17. 融资和上市 Fundraising & Listing
17.1. Celzyva是非中概股，无需中国证监会备案 Celzyva Is Not a China-Based Issuer and Is Not Required to File with the CSRC
① Celzyva Group targets NASDAQ SPAC IPO in 2026Q4. As illustrated in Chapter 4 of this DD data room, Celzyva is not a China-based issuer and is not required to file with the CSRC.
② Celzyva's collaborative partner, Shanghai Quansheng Company, targets HK Exchange 18A IPO in 2027Q4
CSRC: China Securities Regulatory Commission
17.2. 融资上市计划及主要合作方 Fundraising & IPO Plan and Key Professional Advisors & Partners (Legal Counsel, Auditors, Investment Bankers, and SPAC Sponsors)
17.3. 估值参考公司 Valuation Reference Company
Celzyva's achievements significantly surpass those of PrimeGen.
PrimeGen US
2917 Daimler Street, Santa Ana, CA 92705, United States
SPAC: DT Cloud Star Acquisition
Value: US$1.5 billion 15亿美元
Product：MSC therapy for Acute Liver Injury
Achievements: US FDA pre-IND meeting in Dec. 2025
